| Source: |
| Type: enzyme |
| HK2 (Hexokinase 2) is an enzyme that plays a crucial role in glycolysis, the process by which cells convert glucose into energy. HK2 is a key regulatory enzyme in the glycolytic pathway, and it is primarily expressed in various tissues, including muscle, brain, and cancer cells. HK2 has been shown to be overexpressed in many types of tumors, including breast, lung, and colon cancer. This overexpression may contribute to the development and progression of cancer by promoting glycolysis and energy production in cancer cells. HK2 is a key regulatory enzyme in the glycolytic pathway. HK2 plays a role in the regulation of glucose metabolism in diabetes. HK2 is involved in the regulation of cell proliferation, apoptosis, and autophagy. HK2 Inhibitors: -2DG -Curcumin -Resveratrol -EGCG -Berberine -Methyl Jasmonate (MJ) -Honokiol |
| 8725- | MeJa, | Methyl jasmonate leads to necrosis and apoptosis in hepatocellular carcinoma cells via inhibition of glycolysis and represses tumor growth in mice |
| - | vitro+vivo, | HCC, | HCCLM3 | - | in-vitro, | Liver, | Bel-7402 | - | in-vitro, | Liver, | Hep3B | - | in-vitro, | HCC, | SMMC-7721 cell |
| 8723- | MeJa, | Methyl Jasmonate Reduces Inflammation and Oxidative Stress in the Brain of Arthritic Rats |
| - | in-vivo, | Arthritis, | NA |
| 8721- | MeJa, | Potential of Novel Methyl Jasmonate Analogs as Anticancer Agents to Metabolically Target HK-2 Activity in Glioblastoma Cells |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | LN229 |
| 2456- | MET, | Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 2457- | MET, | Metformin Impairs Glucose Consumption and Survival in Calu-1 Cells by Direct Inhibition of Hexokinase-II |
| - | in-vitro, | Lung, | Calu-1 |
| 2385- | MET, | Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model |
| - | in-vitro, | AD, | H4 | - | in-vitro, | NA, | HEK293 | - | in-vivo, | NA, | NA | - | in-vitro, | NA, | SH-SY5Y |
| 2436- | MET, | Metformin alleviates nickel-induced autophagy and apoptosis via inhibition of hexokinase-2, activating lipocalin-2, in human bronchial epithelial cells |
| - | in-vitro, | Nor, | BEAS-2B |
| 994- | MET, | Tumor metabolism destruction via metformin-based glycolysis inhibition and glucose oxidase-mediated glucose deprivation for enhanced cancer therapy |
| - | in-vitro, | Var, | NA |
| 2249- | MF, | Pulsed electromagnetic fields modulate energy metabolism during wound healing process: an in vitro model study |
| - | in-vitro, | Nor, | L929 |
| 525- | MF, | Pulsed electromagnetic fields regulate metabolic reprogramming and mitochondrial fission in endothelial cells for angiogenesis |
| - | in-vitro, | Nor, | HUVECs |
| 8740- | MGO, | Methylglyoxal induces ambience for cancer promotion in HepG2 cells via Warburg effect and promotes glycation |
| - | in-vitro, | Liver, | HepG2 |
| 8694- | MLT, | Melatonin inhibits glycolysis in hepatocellular carcinoma cells by downregulating mitochondrial respiration and mTORC1 activity |
| - | in-vitro, | Liver, | NA |
| 8909- | MO, | Effect of Moringa oleifera on inflammatory diseases: an umbrella review of 26 systematic reviews |
| - | Review, | Nor, | NA |
| 991- | OA, | Blockade of glycolysis-dependent contraction by oroxylin a via inhibition of lactate dehydrogenase-a in hepatic stellate cells |
| - | in-vivo, | NA, | NA | - | in-vivo, | Nor, | NA |
| 2452- | PA, | Targeting Pyruvate Kinase M2 and Hexokinase II, Pachymic Acid Impairs Glucose Metabolism and Induces Mitochondrial Apoptosis |
| - | in-vitro, | BC, | SkBr3 |
| 2451- | PA, | The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors |
| - | Review, | Var, | NA |
| 2396- | PACs, | PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma |
| - | in-vitro, | HCC, | HCCLM3 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | HepG2 | - | in-vitro, | Nor, | L02 |
| 2421- | PB, | Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c‐myc/hexokinase 2 pathway |
| - | in-vitro, | HCC, | HCCLM3 | - | in-vivo, | NA, | NA | - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | Nor, | L02 |
| 1672- | PBG, | The Potential Use of Propolis as an Adjunctive Therapy in Breast Cancers |
| - | Review, | BC, | NA |
| 1661- | PBG, | Propolis: a natural compound with potential as an adjuvant in cancer therapy - a review of signaling pathways |
| - | Review, | Var, | NA |
| 1664- | PBG, | Anticancer Activity of Propolis and Its Compounds |
| - | Review, | Var, | NA |
| 1666- | PBG, | Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer |
| - | Review, | Var, | NA |
| 1231- | PBG, | Caffeic acid phenethyl ester inhibits MDA-MB-231 cell proliferation in inflammatory microenvironment by suppressing glycolysis and lipid metabolism |
| - | in-vitro, | BC, | MDA-MB-231 |
| 2380- | PBG, | Potential Strategies for Overcoming Drug Resistance Pathways Using Propolis and Its Polyphenolic/Flavonoid Compounds in Combination with Chemotherapy and Radiotherapy |
| - | Review, | Var, | NA |
| 2381- | PBG, | Chinese Poplar Propolis Inhibits MDA-MB-231 Cell Proliferation in an Inflammatory Microenvironment by Targeting Enzymes of the Glycolytic Pathway |
| - | in-vitro, | BC, | MDA-MB-231 |
| - | in-vitro, | HCC, | HepG2 |
| 2946- | PL, | Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent |
| - | Review, | Var, | NA |
| 2948- | PL, | The promising potential of piperlongumine as an emerging therapeutics for cancer |
| - | Review, | Var, | NA |
| 3374- | QC, | Therapeutic effects of quercetin in oral cancer therapy: a systematic review of preclinical evidence focused on oxidative damage, apoptosis and anti-metastasis |
| - | Review, | Oral, | NA | - | Review, | AD, | NA |
| 70- | QC, | Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | LAPC-4 |
| 2340- | QC, | Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2) |
| - | in-vitro, | OS, | NA |
| 2300- | QC, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 2431- | QC, | The Protective Effect of Quercetin against the Cytotoxicity Induced by Fumonisin B1 in Sertoli Cells |
| - | in-vitro, | Nor, | TM4 |
| 2344- | QC, | Quercetin: A natural solution with the potential to combat liver fibrosis |
| - | Review, | Nor, | NA |
| 2342- | QC, | Quercetin Inhibits the Proliferation of Glycolysis-Addicted HCC Cells by Reducing Hexokinase 2 and Akt-mTOR Pathway |
| - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vivo, | NA, | NA |
| 2332- | RES, | Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism |
| - | Review, | Var, | NA |
| 2333- | RES, | Resveratrol regulates insulin resistance to improve the glycolytic pathway by activating SIRT2 in PCOS granulosa cells |
| - | in-vitro, | Nor, | NA |
| 2334- | RES, | Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy |
| - | Review, | Var, | NA |
| 2687- | RES, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | NA, | NA | - | Review, | AD, | NA |
| 2439- | RES, | By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice |
| - | in-vitro, | HCC, | HCCLM3 | - | in-vitro, | Nor, | L02 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | HCC, | HUH7 |
| 2441- | RES, | Anti-Cancer Properties of Resveratrol: A Focus on Its Impact on Mitochondrial Functions |
| - | Review, | Var, | NA |
| 2440- | RES, | Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway |
| - | in-vitro, | Lung, | H460 | - | in-vivo, | Lung, | NA | - | in-vitro, | Lung, | H1650 | - | in-vitro, | Lung, | HCC827 |
| 3026- | RosA, | Modulatory Effect of Rosmarinic Acid on H2O2-Induced Adaptive Glycolytic Response in Dermal Fibroblasts |
| - | in-vitro, | Nor, | NA |
| 3195- | SFN, | AKT1/HK2 Axis-mediated Glucose Metabolism: A Novel Therapeutic Target of Sulforaphane in Bladder Cancer |
| - | in-vitro, | Bladder, | UMUC3 |
| 2406- | SFN, | Sulforaphane and Its Protective Role in Prostate Cancer: A Mechanistic Approach |
| - | Review, | Pca, | NA |
| 2404- | SFN, | Prostate cancer chemoprevention by sulforaphane in a preclinical mouse model is associated with inhibition of fatty acid metabolism |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | 22Rv1 | - | in-vivo, | NA, | NA |
| 2403- | SFN, | Reversal of the Warburg phenomenon in chemoprevention of prostate cancer by sulforaphane |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | PC3 | - | in-vivo, | NA, | NA |
| 2444- | SFN, | Sulforaphane Delays Fibroblast Senescence by Curbing Cellular Glucose Uptake, Increased Glycolysis, and Oxidative Damage |
| - | in-vitro, | Nor, | MRC-5 |
| 2445- | SFN, | Sulforaphane-Induced Cell Cycle Arrest and Senescence are accompanied by DNA Hypomethylation and Changes in microRNA Profile in Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | SkBr3 |
| 2446- | SFN, | CAP, | The Molecular Effects of Sulforaphane and Capsaicin on Metabolism upon Androgen and Tip60 Activation of Androgen Receptor |
| - | in-vitro, | Pca, | LNCaP |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:773 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid